Related Experiment Videos
A double-blind controlled clinical trial comparing fluvoxamine with imipramine
British Journal of Clinical Pharmacology
|January 1, 1983
Summary
Fluvoxamine and imipramine show similar antidepressant efficacy in major depression patients. Fluvoxamine offers a favorable safety profile with fewer cardiovascular side effects compared to imipramine.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Major depressive disorder is a prevalent mental health condition.
- Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are common treatment options.
Purpose of the Study:
- To compare the efficacy and safety of fluvoxamine with imipramine in treating primary major depression.
- To evaluate cardiovascular effects and tolerability of both antidepressants.
Main Methods:
- A randomized controlled trial involving 151 patients with primary major depression.
- Patients received either fluvoxamine (max 300 mg/day) or imipramine (max 200 mg/day) for four weeks.
- Efficacy assessed using the Hamilton Rating Scale for Depression (26 items); safety and tolerability monitored.
Main Results:
- Fluvoxamine demonstrated 67.2% improvement on the Hamilton Scale, compared to 62.1% for imipramine.
- Fluvoxamine showed no adverse cardiovascular effects, unlike imipramine which caused postural blood pressure drops.
- Common side effects for fluvoxamine included dry mouth, nausea, somnolence, and tremor; imipramine caused dry mouth, somnolence, dizziness, and tremor.
Conclusions:
- Fluvoxamine exhibits comparable antidepressant efficacy to imipramine.
- Fluvoxamine presents a better safety profile, particularly regarding cardiovascular effects, and is well-tolerated.